Aurinia Pharmaceuticals to Release Third Quarter 2017 Financial Results on November 14, 2017

Download as PDF

Conference Call and webcast to follow

VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc., (NASDAQ: AUPH / TSX: AUP) today announced that it will release its third quarter 2017 financial results on Tuesday, November 14, 2017, after the market closes. At 4:30 p.m. Eastern Time Aurinia’s management will host a conference call to discuss the company’s financial results for the third quarter 2017 and provide a general business update.

The conference call and webcast is scheduled for November 14, 2017 at 4:30pm EST. In order to participate in the conference call, please dial +1-877-407-9170 (Toll-free U.S. & Canada). An audio webcast can be accessed under "News/Events” through the “Investors” section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcast will be available on Aurinia’s website.

About Aurinia
Aurinia is a clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need. The company is currently developing voclosporin, an investigational drug, for the treatment of LN, FSGS, MCD and DES. The company is headquartered in Victoria, BC and focuses its development efforts globally. For further information, see our website at www.auriniapharma.com.

We seek safe harbor.

Aurinia Pharmaceuticals Inc.
Investor Contact:
Celia Economides
VP, Corporate & Public Affairs
IR@auriniapharma.com
or
Media:
Christopher Hippolyte, , 212-364-0458
Christopher.hippolyte@inventivhealth.com

Source: Aurinia Pharmaceuticals Inc.

Released November 6, 2017